AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 15, 2026, 12:05 PM ET Viking Therapeutics highlighted VK2735 obesity program clinical data in two poster presentations at ObesityWeek 2026, with 74% of subcutaneous participants improving at least one BMI category. AI-generated summary · Source: company release
Nasdaq: $VKTXVANQUISH Phase 3SUNRISE oral programClinical and funding risk

VKTX Stock Hub: Viking Therapeutics News, VANQUISH and Oral VK2735

Viking has funded a larger obesity development program, while pivotal outcomes remain ahead. On November 15, 2026 Viking reported an exploratory VENTURE analysis presented at ObesityWeek: after 13 weeks, 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category, compared with 15% on placebo. These are Phase 2 data, not Phase 3 topline. The October 29 filing adds nine-month operating cash use of $377.342M and a dated share count. VANQUISH completion is expected in 2027; oral SUNRISE is underway.

Last updated: November 15, 2026Financial period: September 30, 2026; basic shares October 15Full research report: updated November 15, 2026; latest filing October 29; currency: USD
Full research report · PDF
Viking Therapeutics, Inc. ($VKTX), research updated November 15, 2026
17 pages covering the November 15 ObesityWeek data (exploratory VENTURE BMI-category analysis and VANQUISH-2 baseline), the October 29 Form 10-Q and the September 30 balance sheet, nine-month operating cash use, the October 15 share count, the ATM and the 2032 convertible notes, VANQUISH and the oral SUNRISE program, the maintenance data, the Ligand dispute, the November 13 close, the Health Score, scenarios, sources and FAQ. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next company events · investor conferences in London
UBS November 17 · Jefferies November 18, 2026

Management has a fireside chat at the UBS Global Biopharma Conference on Tuesday, November 17 (10:40–11:10 a.m. ET, as stated by the company) and at the Jefferies Global Healthcare Conference on Wednesday, November 18 (2:00–2:25 p.m. GMT, with a webcast), plus investor meetings at both; a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York follows on December 2 (2:00–2:25 p.m. ET, webcast). Investor conferences are not data readouts. November 3 release

ObesityWeek outcome. On November 15, 2026 Viking said both scheduled posters were presented at ObesityWeek in Washington, D.C.: the VANQUISH-2 baseline characteristics and, on Sunday, an exploratory analysis of the Phase 2 VENTURE trial. After 13 weeks, 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category, compared with 15% on placebo, and no VK2735-treated participant moved to a higher category; participants who improved showed larger reductions in waist circumference, glucose, blood pressure, triglycerides and LDL-C than those whose category did not change. These are not Phase 3 topline results. November 15 release. VANQUISH completion is expected in 2027. Extensions are planned for Q1 2027 with results anticipated in 2028; Part 2 maintenance results are expected in 2027. Source: SEC
Viking Therapeutics, Inc. VKTX daily stock chart
Daily chart $VKTX. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

VKTX stock at a glance

Stock price · live
Real-time price, volume and moving averages for $VKTX on JC Just Charts.
Cash and investments · September 30
$959.813M
$677.609M cash and equivalents plus $282.204M short-term investments; $0.202M restricted cash is separate. Source: SEC
Nine-month operating cash flow
−$377.342M
Cash used in operations for the nine months ended September 30, 2026, from the new October 29 filing. Source: SEC
Q3 net loss
$183.2M
Three months ended September 30; distinct from operating cash use. Source: SEC
Basic shares · October 15
127.522M
127,522,189 common shares on the October 29 filing cover; not fully diluted shares. Source: SEC
Convertible principal
$258.75M
2% notes issued September 25, maturing October 15, 2032. September carrying value was approximately $250.7M. Source: SEC
September financing net proceeds
~$547.5M
$296.9M equity + $250.6M notes, per the October 29 Form 10-Q; already reflected in September 30 cash. Source: SEC
VANQUISH completion window
2027
Company expectation; distinct from an exact topline date or regulatory approval. Source: SEC

Where Viking Therapeutics, Inc. stands now

Viking is a precommercial clinical-stage developer led by injectable and oral VK2735 for obesity. Financing increased resources, while Phase 3 trials require substantial spending. The new filing reports $377.342M of operating cash use over nine months. September cash already includes financing proceeds; those proceeds must not be added again. Source: SEC

At ObesityWeek, Viking presented an exploratory 13-week analysis of the Phase 2 VENTURE trial: 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category versus 15% on placebo. Among participants with Class II obesity at baseline, 80% moved to Class I (20% on placebo); among those with Class III obesity, 57% moved to Class II (13% on placebo). A second poster described the baseline characteristics of the ongoing Phase 3 VANQUISH-2 trial in adults with overweight or obesity and type 2 diabetes. November 15 release

Pivotal efficacy, tolerability and sustained financing remain separate tests. Earlier studies and exploratory maintenance cohorts are not proof of Phase 3 success or approval. Completion windows are not guaranteed topline dates. Trial expense, stock awards and potential note conversion affect resources and per-share outcomes. Source: SEC

The constructive case

Controlled Phase 3 outcomes support clinically meaningful weight loss and tolerability, while oral and maintenance options broaden the development opportunity. The November 15 VENTURE analysis, in which participants who improved their BMI category also showed larger reductions in blood pressure, lipids, glucose and waist circumference, is consistent with the company’s view that weight loss on VK2735 may improve cardiometabolic health. September resources provide execution capacity subject to actual spending. Source: SEC

The cautious case

Pivotal effects or tolerability disappoint, timelines extend or spending exceeds expectations. The ObesityWeek data are an exploratory 13-week Phase 2 analysis, not a Phase 3 result. The programs remain investigational, and cash does not eliminate dilution or development risk. Source: SEC

Latest Viking Therapeutics, Inc. news

Nov 15, 2026

Viking Therapeutics highlights clinical data from VK2735 obesity program at ObesityWeek 2026

Viking Therapeutics presented two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek, taking place from November 14–17, 2026, in Washington, D.C. In an exploratory analysis of the Phase 2 VENTURE trial, 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, compared with 15% of placebo participants. None of the VK2735-treated participants experienced an increase in BMI category. A second poster presented baseline characteristics of the Phase 3 VANQUISH-2 study.

Nov 9, 2026

Viking Therapeutics announces two poster presentations at ObesityWeek 2026

Viking Therapeutics will present two posters on its VK2735 program at The Obesity Society's Annual Meeting, ObesityWeek, held November 14–17, 2026, in Washington, D.C. One poster covers baseline characteristics from the Phase 3 VANQUISH-2 trial of subcutaneous VK2735 in adults with overweight and type 2 diabetes, presented by Jamy Ard, MD, FTOS. The second covers the impact of VK2735 on obesity severity and cardiometabolic parameters in the Phase 2 VENTURE study, presented by Harold Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM.

Nov 3, 2026

Viking Therapeutics to participate at upcoming investor conferences

Viking Therapeutics will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Piper Sandler 38th Annual Healthcare Conference in November and December. Fireside chats are scheduled for Wednesday, November 11th, Tuesday, November 17th, Wednesday, November 18th, and Wednesday, December 2nd, alongside investor meetings. Live webcasts of the Jefferies and Piper Sandler fireside chats will be available on the company website.

Oct 29, 2026

New quarterly filing adds cash-flow detail and dated shares

The September-quarter Form 10-Q reports nine-month operating cash use of $377.342M and 127,522,189 common shares outstanding on October 15. September 30 cash and equivalents of $677.609M plus short-term investments of $282.204M total $959.813M; restricted cash is separate.

Oct 28, 2026

Q3 results and 2027 development windows

Viking reported approximately $960M of September 30 liquidity and Q3 net loss of $183.2M. VANQUISH completion remains expected in 2027; extensions are planned for Q1 2027 with results anticipated in 2028. ObesityWeek posters are scheduled for November 14 and 15.

Oct 14, 2026

SUNRISE oral Phase 3 program initiated

Two 68-week studies each target about 560 adults, with and without type 2 diabetes, using once-daily oral VK2735. This release corrects the October 6 maintenance announcement: oral maintenance dosing is daily, not weekly.

VKTX stock catalysts and development windows

  • November 11–12, 2026 — Stifel 2026 Healthcare Conference fireside chat scheduled for November 11, 10:40–11:10 a.m. ET, with investor meetings; Truist 2026 BioPharma Symposium investor meetings on November 12, both in New York. Past · company-announced investor conferences
  • November 14–15, 2026 — ObesityWeek posters presented: VANQUISH-2 baseline characteristics (Poster Session 1, November 14) and the exploratory VENTURE obesity-severity and cardiometabolic analysis (Sunday, November 15). Viking reported that 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, versus 15% on placebo; not Phase 3 topline. Completed · November 15 release November 15 release · November 9 schedule
  • November 17–18, 2026 — London fireside chats: UBS Global Biopharma Conference on November 17 (10:40–11:10 a.m. ET, as stated by the company) and Jefferies Global Healthcare Conference on November 18 (2:00–2:25 p.m. GMT, 9:00 a.m. ET; webcast). Company-announced investor conferences
  • December 2, 2026 · 2:00–2:25 p.m. ET — Fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York; webcast. Company-announced investor conference
  • Q1 2027 — Planned VANQUISH extension starts and VK3019 28-day multiple-ascending-dose study. Company plans
  • 2027 — Expected VANQUISH completion and Part 2 maintenance results; distinct milestones. Company windows
  • 2028 — Anticipated VANQUISH extension results. Company expectation

November 15 ObesityWeek data · October 28 company update · Investor conferences

October 29 filing: cash use and the share denominator

The new 10-Q reports nine-month operating cash use of $377.342M and September liquidity of $959.813M excluding restricted cash. Its cover gives 127,522,189 common shares outstanding on October 15. These details come from the October 29 Form 10-Q, filed the day after the October 28 results release.

This is not current fully diluted capitalization. Source: SEC

VANQUISH, SUNRISE and maintenance answer different questions

VANQUISH is the injectable Phase 3 program. SUNRISE tests daily oral VK2735 over 68 weeks in adults without and with type 2 diabetes, approximately 560 per study. Part 2 explores maintenance after induction; weight change is exploratory. Daily oral dosing was explicitly corrected October 14. Small cohorts, baseline posters and pivotal outcomes are different evidence. Source: company

According to the November 15 release, the VANQUISH-2 baseline data presented at ObesityWeek indicate that the randomized population is representative of the adult U.S. population with BMI ≥ 27 kg/m² and type 2 diabetes. Both VANQUISH trials dose VK2735 once weekly by subcutaneous injection for 78 weeks, with percent change in body weight versus placebo as the primary endpoint, and are expected to be completed in 2027. Source: company

Merlintrader Health Score · $VKTX

2.95out of 5
Financial resources · 30%4.0

$959.813M of cash and short-term investments at September 30, 2026 against $377.342M of nine-month operating cash use; the September financing is already included in that balance.

Catalysts · 30%2.5

The two ObesityWeek posters were presented on November 14 and 15: an exploratory 13-week VENTURE analysis (74% improved by at least one BMI category versus 15% on placebo) and VANQUISH-2 baseline characteristics, neither a Phase 3 topline. The next scheduled company events are investor conferences; VANQUISH completion is expected in 2027 and pivotal outcomes remain uncertain.

Dilution · 20%2.0

127,522,189 common shares on October 15, 2026 after the September equity offering, plus $258.75M of 2032 convertible notes and stock awards, affect per-share participation.

Trading liquidity · 10%3.0

The company reported 127,522,189 shares outstanding at October 15, 2026. Daily trading remains sensitive to clinical and sector news.

Operating execution · 10%3.0

Injectable, oral and maintenance programs expand execution demands before commercial revenue.

Reassessed November 15, 2026 after the November 15 ObesityWeek data release (catalysts pillar), alongside the September 30 balance sheet and the October 15 share count; scores confirmed. Weighted calculation: 4.0×30% + 2.5×30% + 2.0×20% + 3.0×10% + 3.0×10% = 2.95. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • September financing proceeds are already included in September cash.
  • Trial completion differs from topline disclosure, filing and approval.
  • The November 15 VENTURE analysis is exploratory and covers 13 weeks; its cardiometabolic comparison groups participants by their own BMI-category response.

VKTX Stock FAQ: Viking Therapeutics, Inc. Questions Answered

When is the next VKTX stock catalyst?

The two ObesityWeek posters were presented on November 14 and 15, 2026; on November 15 Viking reported that 74% of VENTURE participants receiving weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, versus 15% on placebo, in an exploratory Phase 2 analysis rather than a Phase 3 topline (November 15 release). The next scheduled company events are fireside chats at the UBS conference on November 17 and the Jefferies conference on November 18 in London, and at the Piper Sandler conference on December 2. VANQUISH completion is expected in 2027; completion, analysis and disclosure are separate milestones. Company presentations and trial windows. November and December investor conferences.

Is Viking Therapeutics’ VK2735 FDA approved?

No: Viking’s October 28, 2026 update describes injectable and oral VK2735 as investigational obesity programs. VANQUISH and the oral SUNRISE program require clinical evidence and subsequent regulatory review. Maintenance cohorts and Part 2 dosing studies are also investigational, without an approved maintenance regimen. Clinical programs and investigational status. Oral Phase 3 program.

How much cash does Viking Therapeutics have, and how long will it last?

Viking held $959.813 million cash and short-term investments at September 30, 2026, excluding $0.202 million restricted cash. Nine-month operating cash use was $377.342 million. September equity and note financing supplied about $547.5 million net after estimated expenses, already reflected in that balance. Larger pivotal programs and follow-up spending determine future funding needs. Latest liquidity, financing and operating cash use.

Is VKTX stock at risk of dilution?

Yes: Viking reported 127,522,189 common shares on October 15, 2026, with equity financing, awards and convertible notes adding potential share exposure. The CEO’s July 29 Form 4 separately reports automatic, nondiscretionary code S sales covering tax obligations after PRSU vesting. These sell-to-cover transactions differ from discretionary selling. Dated common shares and equity instruments. July CEO automatic tax-cover sales.

When does Viking Therapeutics report earnings?

As of November 15, 2026, Viking had not announced its next earnings date. It released Q3 results on October 28 and filed the September-quarter report on October 29. The November ObesityWeek presentations were separate events. Company releases. Company calendar. Latest quarterly results.

What does Viking Therapeutics do?

Viking develops treatments for metabolic and endocrine disorders. Its lead obesity program VK2735 combines GLP-1 and GIP receptor activity and is being studied in injectable and oral forms, including maintenance regimens. The company is precommercial, with pivotal development underway. Company and lead clinical program.

Is Viking’s oral VK2735 maintenance dose taken weekly?

No: Viking’s October 14, 2026 correction specifies daily oral maintenance dosing. The maintenance cohorts and Part 2 study remain investigational, with Part 2 results expected in 2027. A study regimen is not proof of an approved dosing schedule for routine treatment. Corrected daily oral maintenance regimen. Maintenance study timing.

Do Viking’s convertible notes automatically turn into shares?

No: Viking’s September 2026 financing terms make conversion before July 15, 2032 conditional and allow cash, share or combined settlement. The approximately $50.75 initial conversion price is a contractual term, rather than a forecast or automatic trigger. The notes’ $258.75 million principal matures October 15, 2032. Convertible-note conditions and settlement. September note issuance.

Primary sources

This content is published by Merlintrader for educational and informational purposes. It is independent analysis, not investment advice, a recommendation, an offer or a solicitation to trade securities. It is not a research report within the meaning of applicable United States securities regulation. Nothing here recommends buying, selling or holding VKTX.

Figures and guidance retain their source dates. Clinical results, company expectations, registry estimates and illustrative calculations are distinguished. New information may change the analysis; readers should consult the original filings, releases and professional advice relevant to their circumstances.

Viking faces clinical, regulatory, financing, dilution, supply, competition and licensing risks. Earlier clinical results do not guarantee pivotal success, approval or commercial adoption. September financing strengthens resources while adding common shares and convertible obligations. The Ligand dispute remains unresolved, according to the latest company disclosures.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.